Abstract
The difficulty in developing new biopharmaceuticals in Brazil led researchers from USP to found a company to enable the progress of an immunotherapeutic strategy against HPV-induced tumors. The company aims the optimization of the formulation, the conduction of clinical trials and later, the product commercialization. The immunotherapy in question, created in the Vaccine Development Labor…